Arcutis Biotherapeutics, Inc. 8K

Arcutis Biotherapeutics reported strong Q2 2026 ZORYVE-driven revenue growth, raised 2026 sales guidance, achieved profitability and positive cash flow, and advanced multiple clinical, regulatory, commercial, and corporate initiatives.

Arcutis Biotherapeutics, Inc. reported strong financial and operational results for the quarter ended June 30, 2026, highlighted by ZORYVE net product sales of $129.9 million (up 59% year-over-year and 23% sequentially), a swing to net income of $15.0 million, positive operating cash flow of $12.6 million, and an increase in 2026 full-year net product sales guidance to $525–$540 million, while also advancing its dermatology pipeline with FDA approval of an expanded pediatric indication for ZORYVE cream 0.3%, FDA acceptance of an sNDA for ZORYVE cream 0.05% in infants with atopic dermatitis, completion of enrollment in a Phase 2 vitiligo trial, continued enrollment in additional ZORYVE and ARQ-234 studies, the launch of a virtual health and AI-enabled access platform for ZORYVE, the hiring of a targeted primary care and pediatric sales team, appointment of Chris Peetz to the board, and issuance of two new U.S. patents.

Filing Facts

CIK

1787306

Ticker

ARQT

Form

8K

Source Type

fda

Accession

0001787306-26-000049

Alert Tier

7